Student Seminar Report & Project Report With Presentation (PPT,PDF,DOC,ZIP)

Full Version: Formulation and evaluation of buccoadhesive tablet of Atenolol
You're currently viewing a stripped down version of our content. View the full version with proper formatting.
The present study was aimed to formulate the buccoadhesive tablet of atenolol by adopting Box-
Behnken factorial design and using chotosan, carbopol 937P and CMC Na. The formulations
were evaluated for drug content, hardness, thickness, friability, weight variation, invitro
dissolution study and ex-vivo bioadhesive strength and time. The in vitro dissolution study
showed higher and controlled drug release. The ex-vivo bioadhesion studies of formulations on
sheep buccal mucosa showed better bioadhesion with high bioadhesion time.
The oral cavity is being increasingly used for the administration of drugs which are mainly
designed for the contained drugs through the oral mucosa into systemic circulation. Buccal
mucosa consist of stratified squamous epithelium was investigated as a site for drug delivery
several decades ago and the interest in this area for the transmucosal drug administration is still
growing. Buccal mucosa makes a more appropriate choice of site if prolonged drug delivery is
desired because buccal site is less permeable than the sublingual site. Buccal bioadhesive drug
devices designed to remain in contact with buccal mucosa and release the drug over a long
period of time in controlled manner. Such a delivery of drug through buccal mucosa overcomes
premature drug degradation within the GI tract as well as active drug loss due to first pass
metabolism. In addition there is excellent acceptability and the drug can be applied, localized and
may be removed easily at any time during the treatment period.
Atenolol, a β-blocker, prescribed widely in diverse cardiovascular diseases. e.g. hypertension,
angina pectoris, arrhythmias and myocardial infraction. Administration of conventional tablets of
atenolol has been reported to exhibit fluctuations in the plasma drug levels